Chromadex Corp. Hits New 52-Week Low at $4.72 Amid Market Turmoil

Chromadex Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 4.72 on March 3, 2026. This significant decline highlights the stock's volatility, especially when compared to its 52-week high of USD 14.69. Over the past year, Chromadex Corp. has demonstrated a performance increase of 58.12%, significantly outpacing the S&P 500's growth of 17.36%. The company's market capitalization stands at USD 388 million, reflecting its microcap status. With a price-to-earnings (P/E) ratio of 30.00, Chromadex is positioned within a competitive industry, although it currently offers no dividend yield. Financial metrics indicate a return on equity of 28.91%, showcasing the company's ability to generate profit from its equity. Additionally, the debt-to-equity ratio of -0.90 suggests a unique financial structure. As Chromadex navigates its market position, the recent price movement may prompt further scrutiny of its operational strategies and market dynamics.